Drug intelligence / Profile preview

HRS-2261

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS-2261 is an orally administered, novel small molecule drug developed as a selective antagonist of the Purinergic P2X3 receptor. It is being investigated primarily for the treatment of chronic cough, particularly refractory or unexplained chronic cough—a condition with limited approved therapeutic options. The drug acts by inhibiting the purinergic P2X3 receptor, which plays a role in sensory nerve signaling associated with cough reflex hypersensitivity. Clinical studies have demonstrated that HRS-2261 has a favorable safety and tolerability profile in healthy subjects and is currently undergoing phase II clinical trials to assess its efficacy and safety in patients with refractory chronic cough. Developers: Guangdong Hengrui Pharmaceutical

Targets

P2X3 (P2X purinoceptor 3)

Beyond the preview

Go deeper on HRS-2261.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-2261.

Explore the full profile